TWENTY-SIX WEEK CARCINOGENICITY STUDY OF AMPICILLIN IN CB6F1-TgrasH2 MICE

Tamiko ADACHI; Yuki KUWAMURA; Toshihisa FUJIWARA; Noriaki TANIMOTO; Tomonari NISHIMURA; Atsushi KOGUCHI; Kinji KOBAYASHI; Yoshifumi SASAKI; Chisato YAMAGUCHI; Tatsuya HONDA; Kazutaka KAWASHIMA; Hirofumi YUASA; Takaaki YAMAMURA; Toshihide INUI

doi:10.2131/jts.27.147

Regular Paper

TWENTY-SIX WEEK CARCINOGENICITY STUDY OF AMPICILLIN IN CB6F1-TgrasH2 MICE

Tamiko ADACHI, Yuki KUWAMURA, Toshihisa FUJIWARA, Noriaki TANIMOTO, Tomonari NISHIMURA, Atsushi KOGUCHI, Kinji KOBAYASHI, Yoshifumi SASAKI, Chisato YAMAGUCHI, Tatsuya HONDA, Kazutaka KAWASHIMA, Hirofumi YUASA, Takaaki YAMAMURA, Toshihide INUI

著者情報

キーワード: Tg-rasH2 mice, 26-week carcinogenesis study, Ampicillin, ILSI-HESI ACT

ジャーナルフリー

2002 年 27 巻 3 号 p. 147-163

DOI https://doi.org/10.2131/jts.27.147

詳細

抄録

As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）